Sep 17, 2021 / 01:00PM GMT
Operator
Good day ladies and gentlemen. Welcome to Allergy Therapeutics KOL webinar on VLP Peanut, a new generation peanut allergy immunotherapy. (Operator Instructions)
I will now hand over to the CEO of Allergy Therapeutics Manuel Llobet to open the presentation. Please go ahead.
Manuel Llobet - Allergy Therapeutics plc - CEO & Executive Director
Hello, everybody. Good afternoon. Thank you very much for attending our key opinion leaders event on peanut allergy. I hope you find it interesting and we are very pleased to have you with us today.
When we started our peanut vaccine back in 2016, we saw an opportunity to make a big difference in the food allergy area. Though there were already 2 product candidates in development, there was still a big unmet need even if these candidates were going to succeed. Both were long-term treatments with predictable low compliance and most importantly would not have a disease-modifying effect. We were narrowing the same type of opportunity we saw in the allergic rhinitis field where we introduced the Pollinex
Allergy Therapeutics PLC VLP Peanut - a Next Generation Peanut Allergy Immunotherapy Call Transcript
Mar 04, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers